Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Sort by Random

Display 15 Products per page

Company Analysis: Mitsubishi Tanabe

$3,000.00

PharmaVitae explores Mitsubishi Tanabe’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2021
Find out more
Company Analysis: Biogen

$3,000.00

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Johnson & Johnson

$3,000.00

PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Sanofi

$3,000.00

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: Incyte

$3,000.00

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Teva

$3,000.00

PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Orphan Drug Market Outlook to 2017

$3,000.00

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
September 28, 2016
Find out more
Company Analysis: Ionis Pharmaceuticals

$3,000.00

PharmaVitae explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Eisai

$3,000.00

PharmaVitae explores Eisai’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Celgene

$3,000.00

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 8, 2018
Find out more
Company Analysis: Shionogi

$3,000.00

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.
January 29, 2021
Find out more
Company Analysis: Boehringer Ingelheim

$3,000.00

PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include regular earnings coverage and provide timely updates to company product forecasts.
July 21, 2020
Find out more
Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.
July 2, 2018
Find out more
Company Analysis: Regeneron

$3,000.00

PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Under the Radar Takeover Targets

$3,000.00

Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.
July 20, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *